Articles by Anjulie Quick, MD
BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma
ByRyan Haumschild, PharmD, MS, MBA, CPEL ,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Ola A. Abdallah, MD,Anjulie Quick, MD In this episode, 'BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma,' the expert oncologists and oncology pharmacists explored the following questions:
What is the biological rationale for targeting B-cell maturation antigen (BCMA) in multiple myeloma?
What are the different types of BCMA-targeted therapies and what are the Food and Drug Administration (FDA)-approved options?
How do the mechanisms of action differ for the 3 different types of BCMA-targeted therapies?
What unmet needs in relapsed/refractory multiple myeloma (RRMM) are addressed by BCMA-directed therapies?
What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma
ByRyan Haumschild, PharmD, MS, MBA, CPEL ,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Ola A. Abdallah, MD,Anjulie Quick, MD Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma,' Ryan Haumschild led the conversation about the following question:
What are the potential clinical benefits and risks of introducing B-cell maturation antigen (BCMA)-targeted therapies earlier in the treatment continuum?
